Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: Docetaxel
Drug: Thalidomide
Drug: Prednisone
Biological: bevacizumab
Genetic: polymorphism analysis
Other: immunoenzyme technique
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2004-08-09

Last Posted Date: 2018-04-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 73

Registration Number: NCT00089609

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma

Phase 2

Withdrawn

Conditions: Lymphoma

First Posted Date: 2004-08-05

Last Posted Date: 2015-08-19

Lead Sponsor: Hoag Memorial Hospital Presbyterian

Registration Number: NCT00004039

Locations: 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: Splenic Marginal Zone Lymphoma
Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Testicular Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Stage I Adult Diffuse Large Cell Lymphoma
Waldenström Macroglobulinemia

Interventions: Biological: rituximab
Drug: prednisone
Drug: cyclophosphamide
Drug: doxorubicin
Drug: vincristine
Radiation: indium In 111 ibritumomab tiuxetan
Radiation: radiation therapy
Procedure: positron emission tomography

First Posted Date: 2004-08-05

Last Posted Date: 2017-05-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 62

Registration Number: NCT00088881

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-08-04

Last Posted Date: 2013-01-24

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 102

Registration Number: NCT00003784

Locations: 🇺🇸
Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
🇺🇸
Providence Hospital - Southfield, Southfield, Michigan, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States

and more 84 locations

Chemotherapy Plus Interferon Alfa Alone or With Radiation Therapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma

Phase 3

Terminated

Conditions: Lymphoma

First Posted Date: 2004-08-02

Last Posted Date: 2012-07-02

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 469

Registration Number: NCT00003152

Locations: 🇳🇱
Academisch Ziekenhuis Utrecht, Utrecht, Netherlands
🇬🇧
Addenbrooke's NHS Trust, Cambridge, England, United Kingdom

SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia
Neutropenia
Thrombocytopenia

First Posted Date: 2004-07-29

Last Posted Date: 2015-03-06

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 50

Registration Number: NCT00002665

Locations: 🇺🇸
CCOP - Dayton, Kettering, Ohio, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
Cleveland Clinic Cancer Center, Cleveland, Ohio, United States

and more 80 locations

Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Drug: cytarabine
Drug: doxorubicin hydrochloride
Drug: leucovorin calcium
Drug: mercaptopurine
Drug: methotrexate
Drug: prednisone
Drug: vincristine sulfate
Radiation: low-LET cobalt-60 gamma ray therapy
Radiation: low-LET electron therapy
Radiation: low-LET photon therapy

First Posted Date: 2004-07-29

Last Posted Date: 2014-07-24

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 242

Registration Number: NCT00002618

Locations: 🇺🇸
San Antonio Military Pediatric Cancer and Blood Disorders Center, Lackland Air Force Base, Texas, United States
🇺🇸
Cancer Center, University of Virginia HSC, Charlottesville, Virginia, United States
🇨🇭
Clinique de Pediatrie, Geneva, Switzerland

and more 7 locations

RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease

Phase 3

Active, not recruiting

Conditions: Lymphoma

First Posted Date: 2004-07-26

Last Posted Date: 2024-02-22

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 615

Registration Number: NCT00002462

Locations: 🇮🇹
Centro di Riferimento Oncologico - Aviano, Aviano, Italy
🇫🇷
Hopital Necker, Paris, France
🇳🇱
Integraal Kankercentrum Amsterdam, Amsterdam, Netherlands

and more 53 locations

Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-07-16

Last Posted Date: 2012-08-08

Lead Sponsor: Pfizer

Target Recruit Count: 525

Registration Number: NCT00003343

Locations: 🇺🇸
Agouron Pharmaceuticals, Inc., La Jolla, California, United States

GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-07-12

Last Posted Date: 2021-04-28

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 22

Registration Number: NCT00087165

Locations: 🇨🇦
Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa, Ontario, Canada
🇨🇦
London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada
🇨🇦
British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy